Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Befotertinib - InventisBio

Next Previous
Drug Profile

Befotertinib - InventisBio

Alternative Names: Befotertinib mesylate - InventisBio; BPI-D0316; D 0316; Semena

Latest Information Update: 29 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InventisBio
  • Developer Betta Pharmaceuticals Co Ltd; InventisBio
  • Class Amides; Amines; Antineoplastics; Dimethylamines; Fluorinated hydrocarbons; Indoles; Mesylates; Pyrimidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer

Most Recent Events

  • 30 Sep 2025 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Adjunctive treatment) in China (PO) (NCT07181499)
  • 18 Sep 2025 Betta Pharmaceuticals plans a phase II trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Adjuvant therapy) in China (PO), in September 2025 (NCT07181499)
  • 15 Jul 2025 Betta Pharmaceuticals completes a phase-II/III trials in Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease) in China (PO) (NCT04206072)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top